The Investor
22 Apr 2026, 16:42
Sanofi announced that the U.S. Food and Drug Administration has approved an expanded use of Tzield to delay the onset of stage 3 type 1 diabetes in children as young as one year old with stage 2 disease.
The approval extends the previous indication, which covered patients aged eight and older, and is based on data from the Phase 4 PETITE-T1D study. Tzield is the first disease-modifying therapy for type 1 diabetes in this young patient group, targeting the autoimmune process early to slow disease progression.
The decision marks a significant advancement in early intervention for type 1 diabetes, particularly for high-risk children, where delaying the need for insulin therapy could have meaningful clinical and quality-of-life benefits.
The approval extends the previous indication, which covered patients aged eight and older, and is based on data from the Phase 4 PETITE-T1D study. Tzield is the first disease-modifying therapy for type 1 diabetes in this young patient group, targeting the autoimmune process early to slow disease progression.
The decision marks a significant advancement in early intervention for type 1 diabetes, particularly for high-risk children, where delaying the need for insulin therapy could have meaningful clinical and quality-of-life benefits.
